NEW YORK (TheStreet) -- Shares of Aehr Test Systems (AEHR) - Get Report are surging higher by 65.09% to $1.75 on heavy trading volume on Tuesday afternoon, after the burn-in equipment provider announced it has received the first order for its new FOX-XP production test cell.
The order totals over $4.5 million and includes a FOX-XP multi-wafer test and burn in system, a FOX-XP WaferPak, and an initial set of FOX-XP WaferPak Contractors.
Of the total order, $1.4 million is shippable and payable right away, the company said in statement announcing the transaction.
"We are very excited about this new customer for our FOX-XP multi-wafer burn-in and test system and to receive the first order for a full production test cell of this new product. The customer is one of the world's largest semiconductor manufacturers and has selected the FOX-XP solution for a high-volume production application where extended burn-in is required to meet their stringent quality standards," Aehr CEO Gayn Erickson said.
The name of the customer was not disclosed but the company is expecting the remaining shipments and revenue from the sale to continue through early next year.
So far today 2.3 million shares of Aehr Test Systems have exchanged hands compared to the company's daily average of 16,576 shares.
Separately, TheStreet Ratings has set a "sell" rating and a score of D on Aehr Test Systems stock. This is driven by a number of negative factors, which TheStreet Ratings believes should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks it covers.
The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, generally high debt management risk, disappointing return on equity and poor profit margins.
TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.
You can view the full analysis from the report here: AEHR